Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab
about
Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.F10, a novel hydatidiform mole-associated gene, inhibits the paclitaxel sensitivity of A549 lung cancer cells by downregulating BAX and caspase-3.Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.Paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy.Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasisRefining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools.A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health SystemMucin 1-mediated chemo-resistance in lung cancer cells.Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer.Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapyCombination chemotherapy of gemcitabine and vinorelbine for pretreated non-small-cell lung cancer: a retrospective study.Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma.Enhanced antiproliferative and apoptosis effect of paclitaxel-loaded polymeric micelles against non-small cell lung cancers.Decision support systems for incurable non-small cell lung cancer: a systematic reviewPerfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy.Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer.The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
P2860
Q30670518-9D884A15-8F71-456E-886F-11805AF6BC74Q32178099-F9D3B269-08DB-4471-96B7-95DA5A9459F9Q33633684-9FF00C71-37FA-4ADD-AC68-427E1751916DQ34651916-CC40EE05-F6D4-462A-8AED-EE0EE3F7D9EFQ34733497-69CA9A8B-E657-4472-8BC4-7FCCEB1B7CE1Q35927299-343EEA78-4311-4604-BB5E-FE015C736012Q36258014-C1B47F11-C8EB-4DD1-9E1A-45D4E9E22D25Q36414611-19E6E717-C8EE-4DB2-81BD-ADAE35E3316AQ36507586-99050C49-0F8E-4B4A-A623-5A25B59940D5Q36767660-23A0BAE5-5366-4F30-A03C-AAF2F3ADDE3CQ37295840-2209D2AC-A625-4862-8A52-ADBA669B2561Q37566846-A5B0E5A8-44E8-48DD-891F-31C62B856F28Q37642507-1CF8B29F-19F7-4DB2-9607-C477C3F96C54Q37643560-09331387-7A7E-4353-A82D-8B60D85DB62DQ38907439-4CD31B05-0AAE-4BFF-8736-C01E9793590BQ42284446-A42816A1-777C-4972-BD1C-692007D5F97DQ44763677-6CAA8D49-E395-4F6D-8A01-F643ECAC80AAQ46018831-9BFD6B6C-8BF1-46BA-8703-6C7534D1D353Q54310257-9CF0D8C7-D008-4C1C-B407-8FF9D80ADE80
P2860
Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Prognostic models to predict s ...... in with or without bevacizumab
@ast
Prognostic models to predict s ...... in with or without bevacizumab
@en
Prognostic models to predict s ...... in with or without bevacizumab
@nl
type
label
Prognostic models to predict s ...... in with or without bevacizumab
@ast
Prognostic models to predict s ...... in with or without bevacizumab
@en
Prognostic models to predict s ...... in with or without bevacizumab
@nl
prefLabel
Prognostic models to predict s ...... in with or without bevacizumab
@ast
Prognostic models to predict s ...... in with or without bevacizumab
@en
Prognostic models to predict s ...... in with or without bevacizumab
@nl
P2093
P2860
P3181
P1476
Prognostic models to predict s ...... in with or without bevacizumab
@en
P2093
Alan B Sandler
David H Johnson
Joan H Schiller
Julie R Brahmer
Tien Hoang
P2860
P304
P3181
P356
10.1097/JTO.0B013E318260E106
P407
P577
2012-09-01T00:00:00Z